دورية أكاديمية

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

التفاصيل البيبلوغرافية
العنوان: First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
المؤلفون: Albiges, Laurence, Tannir, Nizar M., Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R., Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K., Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I., Choueiri, Toni K., Leung, David, Saggi, Shruti Shally, Lee, Chung-Wei, McHenry, M. Brent, Motzer, Robert J.
المصدر: European Urology ; volume 81, issue 3, page 266-271 ; ISSN 0302-2838
بيانات النشر: Elsevier BV
سنة النشر: 2022
المجموعة: ScienceDirect (Elsevier - Open Access Articles via Crossref)
مصطلحات موضوعية: Urology
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1016/j.eururo.2021.10.001
الإتاحة: https://doi.org/10.1016/j.eururo.2021.10.001Test
https://api.elsevier.com/content/article/PII:S0302283821020698?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0302283821020698?httpAccept=text/plainTest
حقوق: https://www.elsevier.com/tdm/userlicense/1.0Test/ ; http://www.elsevier.com/open-access/userlicense/1.0Test/
رقم الانضمام: edsbas.D0A4C78A
قاعدة البيانات: BASE